The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau

Table 4 HIVDR mutations by treatment status among 16 FSW with detectable HIVDR in Guinea-Bissau

Drug class	HIVDR Mutation (n = 16)	Treatment Naive (n = 5)	ART experienced^a (n = 11)	Total (n = 16)
NNRTI	K103N/S	3 (60.0%)	4 (36.4%)	7 (43.8%)^b
	A98G	0 (0.0%)	2 (18.2%)	2 (12.5%)
	E1238A	0 (0.0%).	1 (9.1%)	1 (6.3%)
	K238N	0 (0.0%)	1 (9.1%)	1 (6.35)
	K238T	0 (0.0%)	1 (9.1%)	1 (6.3%)
	P225H	0 (0.0%)	1 (9.1%)	1 (6.3%)
	V106A	0 (0.0%)	1 (9.1%)	1 (6.3%)
	V179E	0 (0.0%)	1 (9.1%)	1 (6.3%)
	Y188H	0 (0.0%)	1 (9.1%)	1 (6.3%)
	Y188L	1 (20.0%)	0 (0.0%)	1 (6.3%)
NRTI	M184V	0 (0.0%)	6 (54.5%)	6 (37.5%)^b
	M41L	1 (20.0%)	1 (9.1%)	2 (12.5%)
	T215Y	0 (0.0%)	2 (18.2%)	2 (12.5%)
	D67N	1 (20.0%)	0 (0.0%)	1 (6.3%)
	E44D	0 (0.0%)	1 (10.0%)	1 (6.3%)
	K219E	1 (20.0%)	0 (0.0%)	1 (6.3%)
	T215FY	0 (0.0%)	1 (9.1%)	1 (6.3%)
	T215I	1 (20.0%)	0 (0.0%)	1 (6.3%)
PI	L89V	0 (0.0%)	1 (9.1%)	1 (6.3%)^b

Data are n (%)
ART antiretroviral therapy, HIVDR HIV-1 drug resistance, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitors
^aIncluding 10 study participants with current ART use and 1 study participant with previous ART use
^bThe most common HIVDR in each drug class highlighted in italics

ISSN: 1742-6405